Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is focusing on innovative treatments in the cardiovascular field, particularly the potential of SGC001 as a first-in-class (FIC) drug for acute myocardial infarction (AMI) [7][31]. - The company has a diversified pipeline with multiple subsidiaries engaged in innovative drug development, including SGC001, which has received IND approvals in both China and the U.S. [7][12]. - The in vitro diagnostics (IVD) business provides a stable revenue base, with a comprehensive product layout and leading-edge technology platforms [7][12]. Summary by Sections 1. Company Overview - The company, established in 2005 and listed on the Shanghai Stock Exchange in 2019, has been actively developing innovative diagnostic technologies and drug pipelines through its subsidiaries [12][15]. 2. Innovative Drug Development - SGC001 is highlighted as a significant product for AMI treatment, with promising clinical results and a strong market need for new therapies [7][31]. - The company is expanding its drug pipeline to include various therapeutic areas, including oncology and neurodegenerative diseases, leveraging its subsidiaries for differentiated drug development [7][31]. 3. IVD Business - The IVD segment is crucial for the company's revenue, with ongoing development in various diagnostic technologies and health initiatives aimed at improving public health [7][12]. - The company has established several core technology platforms that support its IVD product offerings, enhancing its competitive position in the market [7][12]. 4. Financial Projections - The company is projected to achieve revenues of 5.42 billion, 5.97 billion, and 6.67 billion yuan from 2025 to 2027, with a gradual return to profitability expected by 2027 [1][7]. - The report anticipates that the combined value of the IVD business and innovative drug pipeline could reach approximately 48 billion yuan [7][12].

Core Viewpoint - Bailitianheng has successfully passed the listing hearing on the Hong Kong Stock Exchange, marking a significant step towards its IPO, which will increase the number of listed companies from Chengdu to 28 [1][5]. Company Developments - Bailitianheng is recognized as a leading domestic innovative drug company, with notable achievements in the field of innovative drug development and international expansion [4]. - The company announced that its self-developed innovative biological drug, BL-M24D1 (ADC), has received approval for clinical trials from the National Medical Products Administration [4]. - Bailitianheng has launched a fundraising plan to raise 3.764 billion yuan, which will be entirely allocated to the development of innovative drugs, particularly to accelerate clinical trials for core ADC products [4]. Financial Partnerships - In December 2023, Bailitianheng entered into a collaboration agreement with Bristol-Myers Squibb (BMS) for the dual-target ADC drug BL-B01D1, with a potential total transaction value of $8.3 billion, including an upfront payment of $800 million [6]. - The company is expected to receive milestone payments from BMS, which could total $1.05 billion (approximately 7.5 billion yuan) if all conditions are met [6]. Industry Trends - The trend of companies from Chengdu seeking listings in Hong Kong reflects a strong momentum for local enterprises to expand into international capital markets [8]. - As of now, Chengdu has 122 A-share listed companies, 27 listed in Hong Kong, and 5 in the US, with the total number of listed companies expected to reach 154 following Bailitianheng's IPO [8].

Core Viewpoint - Beijing Hotgen Biotech Co., Ltd. announced that its affiliate, ShunJing Biopharmaceutical Technology Co., Ltd., has achieved positive preliminary results in the Phase Ib clinical trial of the innovative drug SGC001, which is aimed at treating acute myocardial infarction [1][2]. Clinical Progress - The Phase Ib clinical trial of SGC001 has been completed, showing good safety and tolerability in patients with anterior ST-segment elevation myocardial infarction (STEMI) [1]. - No grade 3 or higher adverse events were reported across low (300 mg), medium (600 mg), and high (900 mg) dosage groups, indicating a strong safety profile [1][2]. - Pharmacokinetic analysis revealed that the median Tmax for SGC001 ranged from 1.30 to 4.07 hours, with a half-life (t1/2) of approximately 8 to 11 days [2]. Preliminary Efficacy Results - Initial efficacy results indicated that SGC001 at 600 mg and 900 mg doses showed a trend towards myocardial protection compared to the placebo group, with median reductions in myocardial infarction area percentages of 20.5% and 38.1%, respectively [2]. - The time required for high-sensitivity cardiac troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP) to return to normal levels was shorter in the treatment groups compared to the placebo [2]. Drug Overview - SGC001 is a monoclonal antibody developed for emergency treatment of acute myocardial infarction, specifically targeting anterior STEMI [3]. - The drug has received clinical trial approvals from both the U.S. FDA and China's National Medical Products Administration (NMPA), and it was granted Fast Track Designation by the FDA in March 2025 [3]. - The project has also received support from Beijing's Science and Technology Program and is recognized as an innovative pharmaceutical product [3].

本次股票发行后拟在科创板市场上市，该市场具有较高的投资风险。科创板公司具有研发 投入大、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投 资者应充分了解科创板市场的投资风险及本公司所披露的风险因素，审慎作出投资决定。 广州必贝特医药股份有限公司 BeBetter Med Inc. （广州市高新技术产业开发区科学城崖鹰石路 25 号 A-3 栋第八层 802 房） 首次公开发行股票并在科创板上市 招股说明书 保荐人（主承销商） （广东省深圳市福田区中心三路8号卓越时代广场（二期）北座） 联席主承销商 （深圳市罗湖区红岭中路 1012 号国信证券大厦十六层至二十六层） 广州必贝特医药股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由 发行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策 ...

Core Viewpoint - Hunan Jiutian Pharmaceutical Co., Ltd. is focusing on the transformation towards innovative drug development, with a significant increase in R&D investment and a stable operational performance in Q3 2025, despite challenges in the broader pharmaceutical industry [2][3]. Group 1: Q3 Operational Performance - The overall operational status in Q3 2025 remained stable, with market demand relatively consistent and sales progressing as planned [2]. - The pharmaceutical manufacturing industry saw a revenue of 12,275.2 billion yuan in the first half of 2025, a year-on-year decrease of 1.2%, and a profit total of 1,766.9 billion yuan, down 2.8% year-on-year [2]. - Despite industry pressures, the sales of medicated plaster in the terminal market showed a yearly increase, with sales expected to exceed 7 billion yuan in 2024, a growth of approximately 10%, and over 4 billion yuan in the first half of 2025, a growth of about 15% [2]. Group 2: Focus on Innovative Drug Transformation - The company is fully transitioning to focus on innovative drug R&D, with chemical innovative drugs as the core direction and some involvement in traditional Chinese medicine [3]. - Key therapeutic areas include pain management, focusing on polypeptide and small molecule drugs, and oncology, concentrating on PDC drug development [3]. - The company plans to invest between 250 million to 300 million yuan in R&D for 2025, indicating a strong commitment to its innovative transformation [3]. Group 3: Competitive Advantages and Market Strategies - The external pain relief market is expected to grow due to increasing health demands and an aging population, providing significant development space [4]. - The company aims to enhance product strength and brand influence in the gel plaster sector, optimizing product structure to meet diverse health needs [4]. - Specific product strategies include leveraging the advantages of JIJ02 gel for acne treatment and expanding indications in the polypeptide drug field, focusing on pain and pulmonary fibrosis [4]. - To address the impact of centralized procurement on key products like Loxoprofen Sodium Gel, the company plans to enhance sales through a comprehensive channel coverage system, increase R&D investment for new product launches, and strengthen cost control through an integrated supply chain [4].

Group 1: Company Overview and Market Conditions - The overall business operation of the company in Q3 2025 remains stable, with market demand relatively steady and sales progressing as planned [2] - The pharmaceutical manufacturing industry saw a revenue of CNY 12,275.2 billion in the first half of 2025, a year-on-year decrease of 1.2%, and a total profit of CNY 1,766.9 billion, down 2.8% [2] - Despite the overall industry pressure, the transdermal patch market is showing a positive growth trend, with sales expected to exceed CNY 7 billion in 2024, a year-on-year increase of approximately 10%, and over CNY 4 billion in the first half of 2025, up about 15% [3] Group 2: Strategic Focus and R&D Investment - The company is fully transitioning to focus on innovative drug research and development, with a core emphasis on chemical and traditional Chinese medicine innovations [4] - The estimated R&D expenditure for the year 2025 is projected to be between CNY 250 million and CNY 300 million [5] - The company is committed to enhancing its product strength and brand influence through continuous R&D, aiming to meet diverse health needs and create long-term value for investors [6][7] Group 3: Competitive Landscape and Product Development - The external pain relief market has significant growth potential, driven by increasing health demands and an aging population [6] - The JIJ02 gel shows advantages over existing acne treatments, such as lower risk of resistance and milder side effects, with plans to expand its indications in the peptide drug area [7] - Following the implementation of centralized procurement for the Loxoprofen Sodium Gel Patch, the company will adopt multi-faceted measures to stabilize its business foundation and ensure long-term growth [7]

格隆汇10月22日丨热景生物(688068.SH)公布，公司收到参股公司舜景医药关于自主研制的创新药 SGC001 注射液 Ib 期临床研究获得了积极的初步结果的汇报。 舜景医药开展的创新药 SGC001 注射液分别在健康志愿者中和在前壁ST段抬高型心肌梗死患者中开展 了 2 个 I 期研究。截至本公告披露日，SGC001 注射液已完成 Ib 期临床试验并取得《一项评估 SGC001 在中国前壁ST 段抬高型心肌梗死且计划接受经皮冠状动脉介入治疗的患者中的安全性、耐受性、药代 动力学特征、免疫原性和初步疗效的随机、双盲、安慰剂对照、单次给药剂量递增的Ib期临床研究统计 分析表格》。 SGC001 是一款由舜景医药孙志伟教授研发团队联合首都医科大学北京市心肺血管疾病研究所杜杰教 授、李玉琳教授团队共同开发研制的急救用单克隆抗体药物，适用于急性心肌梗死（Acute Myocardial Infarction, AMI）(首先开展的适应症为"前壁 ST 段抬高型心肌梗死")患者的急救治疗。此前，针对AMI 疾病，暂无相关抗体药物进入临床研究阶段及审批上市。截至本公告日，SGC001 临床试验申请 （IND）已先后获 ...

Core Insights - The article discusses the increasing trend of innovative pharmaceutical companies going public in the Hong Kong market to secure funding, highlighting the importance of cash flow for sustaining operations and research and development [4][5][6] - It emphasizes the need for a diversified financing approach, combining business development (BD) collaborations and IPOs to create a "safety net" for innovation [6][10] - The article also examines the financial challenges faced by specific companies, such as Wangshan Wangshui and Ying'en Biotechnology, detailing their revenue fluctuations and strategic responses to market competition [10][15] Group 1: Market Trends - In 2023, 21 innovative pharmaceutical companies have listed on the Hong Kong Stock Exchange, with notable first-day performances, such as Silver诺医药's 206% increase [4] - The Hong Kong market continues to expand, with companies like Wangshan Wangshui preparing for IPOs, raising questions about their ability to replicate previous successes [4][5] Group 2: Wangshan Wangshui's Financial Performance - Wangshan Wangshui's revenue is projected to drop from 200 million yuan to 11.83 million yuan in 2023-2024, a decline of over 94% [10] - The company reported a profit of 6.427 million yuan in 2023 but is expected to incur a loss of 218 million yuan in 2024 [10][11] - The decline in revenue is attributed to a significant drop in licensing income, particularly from its collaboration with Junshi Biosciences on the COVID-19 treatment VV116 [11][12] Group 3: Wangshan Wangshui's Product Pipeline - Wangshan Wangshui is attempting to expand the indications for VV116 to include respiratory syncytial virus (RSV) treatment, but faces competition from faster-moving rivals [12][13] - The company has two additional core products targeting depression and erectile dysfunction, but both are entering highly competitive markets [13][14] Group 4: Ying'en Biotechnology's Strategy - Ying'en Biotechnology focuses on antibody-drug conjugates (ADCs) and has developed a pipeline of 13 candidate drugs, with significant partnerships for licensing agreements [15][16] - The company reported a revenue increase of 22.91% year-on-year, reaching 1.227 billion yuan from licensing and collaboration agreements [18] - Despite revenue growth, Ying'en Biotechnology's net loss for the first half of 2025 was 2.074 billion yuan, indicating challenges in profitability [18][19]

Core Insights - The biopharmaceutical industry is characterized by long R&D cycles, high capital investment, and significant risk, making cash flow essential for sustaining operations and innovation [1][2] - The Hong Kong stock market has seen a surge in innovative drug companies going public, with 21 companies listed this year, and notable first-day performances [1] - The STAR Market in China has also opened new financing channels for innovative drug companies, with several firms successfully passing the listing process [2] Group 1: Market Trends - The trend of innovative drug companies going public in Hong Kong is referred to as the "listing wave," with companies like Yinnuo Pharmaceutical seeing first-day gains of up to 206% [1] - The reintroduction of the fifth set of listing standards on the STAR Market has facilitated the listing of companies like Heyuan Biotechnology and Beixin Life [2] Group 2: Company-Specific Insights - Wangshan Wangshui, established in 2013, focuses on small molecule drugs in the fields of neuropsychiatry and reproductive health, but faces challenges in market competition and R&D progress [5] - Financial data indicates significant operational pressure for Wangshan Wangshui, with revenue dropping from 200 million to 11.83 million in 2023-2024, a decline of over 94% [6] - The decline in revenue is primarily attributed to a sharp decrease in licensing income, particularly from the collaboration with Junshi Biosciences on the COVID-19 drug VV116 [7] Group 3: R&D and Product Pipeline - Wangshan Wangshui is attempting to expand the commercial value of VV116 by exploring new indications, such as treatment for respiratory syncytial virus (RSV) [8] - The company has two other core products targeting depression and erectile dysfunction, but both face intense market competition [8] - The company’s financial resources are under pressure due to high R&D expenditures and limited revenue from existing products, necessitating successful fundraising through its IPO [9] Group 4: Competitive Landscape - In contrast to Wangshan Wangshui, Yingen Biotechnology, founded in 2019, specializes in antibody-drug conjugates (ADCs) and has developed a pipeline of 13 candidate drugs [11] - Yingen Biotechnology has accelerated its cash flow through licensing agreements with major companies, resulting in a revenue increase of 22.91% year-on-year [12] - Despite revenue growth, Yingen Biotechnology has experienced a significant increase in net losses, highlighting the challenges of balancing R&D investment with financial performance [12] Group 5: Future Outlook - Analysts emphasize the importance of diversified financing strategies for innovative drug companies to build a "safety net" for R&D [2] - The ability of companies like Yingen Biotechnology to leverage their ADC innovations and partnerships will be crucial for their long-term success and market validation [13]

Company Dynamics - On October 19, the company presented impressive interim analysis data from the HARMONi-6 trial at The Lancet & ESMO [1] - The company revised the HARMONi-3 trial protocol to conduct independent statistical analyses based on histological types [2] Clinical Trial Results - The interim analysis of HARMONi-6 showed a median progression-free survival (mPFS) of 11.1 months compared to 6.9 months, with a hazard ratio (HR) of 0.60 (P<0.0001), indicating a significant improvement [1] - The absolute difference in mPFS between the two groups was 4.24 months, with consistent results across subgroups regardless of PD-L1 expression or liver metastasis [1] - Treatment-related serious adverse events (SAE) were reported at 32.3% for the experimental group versus 30.2% for the control group, with no overall survival (OS) data available yet [1] HARMONi-3 Trial Updates - The HARMONi-3 trial will be divided into two parts: sq-NSCLC (600 patients) and nsq-NSCLC (1000 patients), with separate statistical analyses planned [2] - Enrollment for sq-NSCLC is expected to complete in the first half of 2026, with OS analysis anticipated around the same time [2] - The nsq-NSCLC group aims to complete enrollment in the second half of 2026, with PFS event numbers expected in the first half of 2027 [2] Expansion of Clinical Indications - The company plans to initiate a global multi-regional clinical trial (HARMONi-GI3) for AK112 in colorectal cancer, based on promising II phase data [2] - The trial will compare AK112 combined with chemotherapy against bevacizumab combined with chemotherapy, with an enrollment target of 600 patients [2] Earnings Forecast and Valuation - The company maintains its earnings per share (EPS) forecasts for 2025 and 2026 at 0.09 CNY and 0.59 CNY, respectively [2] - The target price has been adjusted down by 18.2% to 184.00 HKD, reflecting a 50.1% upside potential [3]